Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Quest/Unilab

This article was originally published in The Gray Sheet

Executive Summary

Quest Diagnostics will submit more information on its proposed acquisition of diagnostic testing services firm Unilab following a request from the Federal Trade Commission. Completion of the $1.1 bil. purchase, first announced April 2, is expected to be delayed until the third quarter (1"The Gray Sheet" April 8, 2002, p. 19)...

You may also be interested in...



LabCorp Enhances Cancer Testing Capability With $600 Mil. Dianon Purchase

LabCorp says it does not foresee antitrust issues with the Federal Trade Commission related to the acquisition of cancer testing firm Dianon

Quest Diagnostics Spends $1.6 Bil. To Expand Presence In California, D.C.

Quest Diagnostics will control 12% of the $3.8 bil. California lab testing market following the acquisition of Unilab Corp. The $1.1 bil. deal was announced April 2, one day after Quest completed its $500 mil. cash acquisition of Amercian Medical Labs (AML)

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel